Multiple Kinase Involvement in the Regulation of Vascular Growth by Adderley, Shaquria P. et al.
6 
Multiple Kinase Involvement  
in the Regulation of Vascular Growth 
Shaquria P. Adderley, Chintamani N. Joshi,  
Danielle N. Martin, Shayna Mooney and David A. Tulis 
East Carolina University, Brody School of Medicine, 
 Department of Physiology , Greenville NC, 
 USA 
1. Introduction 
The initial discovery of protein phosphorylation as a regulatory mechanism for the control 
of glycogen metabolism has led to intense interest of protein phosphorylation in regulating 
protein function (Cohen et al., 2001). Kinases play a variety of roles in many physiological 
processes within cells and represent one of the largest families in the human genome with 
over 500 members comprising protein serine/threonine, tyrosine, and dual-specificity 
kinases (Manning et al., 2002). Phosphorylation of proteins is one of the most significant 
signal transduction mechanisms which regulate intracellular processes such as transport, 
growth, metabolism, apoptosis, cystoskeletal arrangement and hormone responses (Bononi 
et al., 2011; Heidenreich et al., 1991; Manning et al., 2002; Pawson et al., 2000). As such, 
abnormal phosphorylation of proteins can be either a cause or a consequence of disease. 
Kinases are regulated by activator and inhibitor proteins, ligand binding, and 
phosphorylation by other proteins or via autophosphorylation (Hanks et al., 1991; Hug et al., 
1993; Scott, 1991; Taylor et al., 1990; Taylor et al., 1992). Since kinases play key functions in 
many cellular processes, they represent an attractive target for therapeutic interventions in 
many disease states such as cancer, inflammation, diabetes and arthritis (Cohen et al., 2010; 
Fry et al., 1994; Karin, 2005; Mayers et al., 2005). In particular, the serine/threonine family of 
kinases comprises approximately 125 of the 500 family of kinases and includes the cyclic 
adenosine monophosphate (cAMP)-dependent protein kinase (PKA), the cyclic guanosine 
monophosphate (cGMP)-dependent protein kinase (PKG), and protein kinase C (PKC). 
These kinases are implicated in the regulation of cell growth and are the focus of this current 
study.  
Nitric oxide (NO) is the primary endogenous activator of soluble guanylate cyclase (sGC) 
and cGMP generation in the vasculature with PKG historically acknowledged as its primary 
downstream kinase (Ignarro, 1991; Ignarro et al., 1985). However, this area of research is 
controversial since the effects of NO are tightly regulated and specific to certain sub-cellular 
microenvironments. The NO-sGC-cGMP signaling pathway is of major importance in the 
cardiovascular system where it modulates functions such as vascular smooth muscle cell 
(VSMC) relaxation and growth (Ignarro, 1991; Ignarro et al., 1986; Ignarro et al., 1985; Lucas 
et al., 2000). Vascular remodeling is associated with injury and the pathogenesis of disorders 
www.intechopen.com
 
Advances in Protein Kinases 
 
132 
such as atherosclerosis and it is well established that the proliferation and migration of 
VSMCs play a major role in these processes (Gibbons et al., 1994; Herity et al., 1999; Shi et al., 
1996). The molecular mechanisms of cGMP signaling are not well understood, since studies 
suggest that NO can both promote and inhibit pathological vascular remodeling 
(Kawashima et al., 2001; Ozaki et al., 2002; Rudic et al., 1998). Furthermore, recent studies 
provide sound evidence for NO-independent heme oxygenase (HO) and carbon monoxide 
(CO) as physiologically relevant signals capable of activating sGC and promoting cGMP 
signal transduction (Christodoulides et al., 1995; Siow et al., 1999; Tulis et al., 2001a; Tulis et 
al., 2001b; Tulis et al., 2005). BAY 41-2272 (BAY) is a prototype of a novel class of sGC 
modulators that potentiate both NO- and CO-mediated signaling and that has potential for 
use  in clinical trials for the treatment of cardiovascular disease, yet mechanisms of action 
for BAY and similar agents still remain to be determined (Boerrigter et al., 2007; Mendelev et 
al., 2009; Roger et al., 2010). One study suggests that BAY may have phosphodiesterase 
(PDE) 5 inhibitory activity at high concentrations (Mullershausen et al., 2004); however this 
is still controversial. BAY interacts with sGC via a different mechanism than that of NO; 
therefore, the amount of cGMP generated and subsequent targets that are activated may be 
distinct leading to different responses than that of traditional NO-based signaling. This is 
important and a perfect example of a drug-induced versus a cell-specific response.  
Individual drugs interact with cells differently depending on the cellular 
microenvironments within the cell. Recent reports demonstrate the ability of cell- and 
agonist-specific responses following ligand stimulation due to intracellular localization of 
proteins including kinases which operate largely to ensure signal specificity (Di Benedetto et 
al., 2008; Lissandron et al., 2006; Xiang, 2011). An increase in cyclic nucleotide signaling can 
affect multiple signaling pathways because of activation of such kinases in particular 
intracellular domains. Hence, compartmentalization of proteins is very critical in 
cellular/biomolecular signaling in order to ensure a specific response to a particular 
stimulus in cells.  
VASP, a cytoskeletal protein that belongs to the Ena/VASP family, was originally 
characterized as a substrate for cyclic nucleotide-dependent PKA and PKG (Krause et al., 
2002; Reinhard et al., 2001). At least four distinct phosphorylation sites on VASP (Ser157, 
Ser239, Thr278, Ser322) have been identified (Butt et al., 1994; Chitaley et al., 2004; Thomson et 
al., 2011). Despite the conventional thought that phosphorylation of VASP at Ser239 and 
Ser157 occurs by PKG and PKA, respectively (Butt et al., 1994), more recent studies suggest 
that crosstalk exists and that Ser157, Ser239 and Thr278  can be phosphorylated by both PKA 
and PKG. However, phosporylation of VASP by PKC and AMP kinase is more selective 
(Benz et al., 2009; Blume et al., 2007; Zhuang et al., 2004). The phosphorylation pattern of 
VASP is complex and dynamic and occurs in site-specific order with different priorities 
(Abel et al., 1995; Butt et al., 1994; Zhuang et al., 2004). Functionally, VASP plays an 
important role in regulating cytoskeletal dynamics and processes such as cell adhesion and 
migration (Kwiatkowski et al., 2003; Mitchison et al., 1996; Vasioukhin et al., 2000), and 
phosphorylation of VASP has been shown to be important physiologically as it is involved 
in these processes. It was reported that VASP phosphorylation at Ser157 is required for the 
growth stimulatory effect and phosphorylation at Ser239 is required for the growth inhibitory 
effect of NO on SMCs (Chen et al., 2004). Although VASP phosphorylation continues to be 
used as a biochemical marker for selective kinase activation, its precise cellular and 
molecular functions remain to be fully determined.  
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Previously, we demonstrated in both rat commercial (A7R5) VSMCs and rat primary 
VSMCs that BAY increases cyclic nucleotides and inhibits vascular growth through 
processes involving VASP phosphorylation (Joshi et al., 2011; Mendelev et al., 2009). In this 
report we demonstrate for the first time that BAY increases the activity of protein kinases 
and that this system has the ability to regulate growth of VSMCs. Novel results include 
demonstration that kinase activity from PKA, PKG and PKC has the capacity to increase 
phosphorylation of cellular proteins including VASP. Notably, the implication of multiple 
kinases in the regulation and activation of VASP provides sound evidence for potential 
crosstalk among otherwise distinct kinases within the cell. Functionally, strong evidence is 
presented linking cyclic nucleotide-mediated kinase activation and VASP phosphorylation 
with inhibition of vascular smooth muscle growth through modulation of proliferation and 
migration.     
2. Methods 
2.1 Rat primary VSMC culture 
Following established procedures (Liu et al., 2009; Tulis et al., 2002), thoracic aorta VSMCs 
were obtained from male Sprague-Dawley rats (100-125 grams) and cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) and Primocin 
(100mg/L) at 37ºC in 95% air/5% CO2. Cells were split and propagated through passage 6 
(unless otherwise specified). For select experiments higher passage cells were used between 
passage 7 and 10. All studies abided by the guidelines of the Institutional Animal Care & 
Use Committee and conformed to the Guide for the Care and Use of Laboratory Animals 
(US National Institutes of Health, Publication No. 85-23, revised 1996).  
2.2 In-cell western 
Phosphorylation of VASP was examined by use of an established cell-based 
immunocytochemical assay for monitoring kinase signaling pathways (Chen et al., 2005). Rat 
VSMCs were seeded (~20,000 cells/well) in 96 well plates and once adhered, pretreated 
with either kinase and PDE inhibitors or vehicle for 30 minutes after which they were 
stimulated with either BAY for 60 minutes or cyclic nucleotide analogs (8Br-cAMP; 10µM or 
8Br-cGMP; 10µM, Tocris) for 30 minutes. The inhibitors used for In-Cell Westerns were: 
adenosine 3’,5’-cyclic monophosphate-dependent protein kinase inhibitor (5-24), (PKI; 
10µM), a selective PKA inhibitor (Enzo); DT-2 trifluoroacetate salt, (DT2; 10µM), a selective 
PKG inhibitor (Sigma-Aldrich); calphostin C (CALC; 100nM), a selective inhibitor of PKC 
(Enzo); cilostazol (CILO; 10 µM), a selective PDE3 inhibitor (Sigma-Aldrich); rolipram (ROL; 
10 µM), a selective PDE4 inhibitor (Tocris); zaprinast (ZAP; 10 µM; MP Biochemicals) and 
vardenifil (VAR; 50 nM; Toronto Research Chemicals), selective PDE5 inhibitors. The vehicle 
for CILO, ROL, CALC and ZAP was DMSO (< 0.5%). After incubation, media was removed 
and cells were fixed with 4% formalin in PBS for 20 minutes. Cells were washed and 
permeabilized with PBS containing 0.1% Triton X-100, followed by 1X PBS + 0.1% Tween-20. 
Cells were blocked with IR blocking solution (Odyssey) for 3 hours and then incubated with 
primary antibodies directed against VASP at pSer239 (1:500; Cell Signaling), VASP at pSer157 
(1:500; Cell Signaling) or α-tubulin (1:500; Sigma) overnight at 4ºC. Cells were washed with 
PBS + 0.1% Tween-20 followed by incubation with two secondary antibodies: IRDye 800CW 
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(1:500; Odyssey) and Alexa Fluor 680 for 1 hour. Cells were washed with PBS containing 
0.1% Tween-20 followed by plain PBS. The plate was allowed to dry overnight and scanned 
using the appropriate channels for detection with the Odyssey Imager. 
2.3 Western blot  
Rat VSM cells were used between passages 4 and 6 for all experiments. Cells were lysed in 
buffer (50mM Tris, pH 6.8; 1% SDS; 0.1% Triton; protease inhibitor cocktail (Roche); 
phosphate inhibitor cocktail (Santa Cruz)) and sonicated on ice followed by centrifugation 
(14000g, 20 min). Protein concentration of whole cell lysates was determined by the BCA 
assay (Pierce). Proteins were separated on SDS-PAGE gels and transferred to Immobilon-P 
membranes (Millipore) using Mini-Protean Electrophoresis and Mini Trans-Blot Cells (Bio-
Rad). Blots were blocked with 5% non-fat milk in TTBS (25mM Tris/Tris-HCl; 0.0027M KCl; 
0.13M NaCl; 0.1% Tween 20) or 5% BSA in TTBS for 1 hour and incubated with primary 
antibodies directed against protein kinase G (PKG) and protein kinase A (PKA) (1:1000; 
Abcam), phospho-PKASer338 (1:1000; Biosource), VASP, phospho-VASPSer157, and phospho-
VASPSer239 (1:1000; Cell Signaling) and α-tubulin (1:1000; Sigma) overnight at 4 ºC. Blots 
were washed with TTBS, incubated with peroxidase-linked secondary antibodies (1:5000) 
for 1 hour, visualized using Pierce ECL Western blotting kit, documented using an Alpha 
Imager 2200, and analyzed with ImageJ 1.40g software (NIH). 
2.4 Hemocytometry assay 
Rat VSMCs were seeded in 24 well plates (40,000 cells/well) and after adherence were 
quiesced overnight in 0.2% FBS. Cells were then pretreated with PKI, DT2 or vehicle for 30 
mins, prior to stimulation with BAY (10µM) for 48 or 72 hrs. At the end of the time point, 
cells in each well were trypsinized and the cell count estimated using a hemocytometer at 
10X magnification. 
2.5 MTT assay 
Rat VSMCs were seeded in 96 well plates and pretreated with PKI, DT2 or vehicle for 30 
mins, prior to stimulation with BAY (10µM) for 24hrs. After treatment media was removed 
and MTT was added to each well and incubated for 4 hours at 37˚C. The MTT was removed, 
MTT solvent added and absorbance read after 15 mins.  
2.6 BrdU assay 
Rat VSMCs were seeded in 96 well plates and pretreated with PKI, DT2, CALC or vehicle 
for 30 mins, prior to stimulation with BAY (10µM) for 48hrs. After treatment media was 
removed and BrdU labeling solution was added to each well and incubated for 3 hours at 
37˚C. Next the labeling solution was removed, cells were fixed and the anti-BrdU antibody 
added for 90 mins. Cells were washed, the substrate was then added, and absorbance was 
read after 30 mins.  
2.7 Kinase assay 
Rat VSMCs were seeded in 6 well plates and grown to confluence. The cells were then 
pretreated with PKI, DT2, CALC or vehicle for 30 mins, prior to stimulation with BAY 
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(10µM) for 1 hour. The cells were lysed, protein was isolated and protein concentration was 
determined via a BSA assay. Kinase activity was determined using an activity kit (Enzo Life 
Sciences). Briefly, samples were added to the wells, the reaction was initiated with ATP, and 
cells were incubated at 30˚C for 90 mins. A phosphospecific substrate antibody was added 
and incubated at RTP for 60 mins. Next the plate was washed and the HRP conjugate was 
added and incubated for 30 mins. Finally the plate was washed and substrate added for 30 
mins and absorbance was read. 
2.8 Scratch wound assay 
Rat VSMCs were seeded in 24 well plates. Cells were injured with a 1 mm scrape and the 
images captured. Immediately cells were then treated with PKI, DT2, CALC or vehicle for 30 
mins, prior to stimulation with BAY (10µM) for 6 or 16 hrs. Afterward the images were 
captured and distances migrated were measured. 
2.9 Data analysis 
Statistical significance between experiments was determined using an analysis of variance 
(ANOVA). In the event that the F ratio indicated a significant P<0.05 change occurred, a 
post hoc test was performed to identify individual differences. Results were reported as 
mean ± the standard error of the mean (SEM). 
3. Results 
3.1 The effect of kinase inhibitors on BAY-induced VASP phosphorylation 
We recently demonstrated that BAY, a potent stimulator of sGC, increased phosphorylation 
of VASP in a site-specific fashion in rat A7R5 VSMCs (Mendelev et al., 2009) and in rat 
primary VSMCs (Joshi et al., 2011). In the current study we sought to identify kinases 
responsible for this selective phosphorylation of VASP induced by BAY. In primary VSMCs, 
BAY (10 µM) significantly increased VASP phosphorylation at both Ser157 and Ser239 (Figures 
1A, 1B, respectively). Addition of PKI (10 µM) or CALC (100 nM) slightly (non-significantly) 
increased BAY-induced phosphorylation of VASP at Ser157 compared to effects of BAY alone 
(Fig. 1A), whereas CALC slightly (non-significantly) reduced VASP phosphorylation at 
Ser239 compared to BAY alone (Fig. 1B).  
Due to the relative ineffectiveness of select kinase inhibition on site-specific VASP 
phosphorylation, the possibility of crosstalk between these kinases was examined. 
Intriguingly, the combination of PKI and DT2 increased the phosphorylation induced by 
BAY at Ser157 (Fig 2A), while the combination of PKI and CALC markedly increased the 
phosphorylation induced by BAY at Ser239 (Fig. 2B).  
3.2 Effect of PDE inhibition and kinase activity on VASP phosphorylation 
In order to determine if kinase inhibition affects the ability of PDEs to regulate VASP, 
VSMCs were pretreated with inhibitors of kinases and PDEs prior to stimulation with BAY. 
In the presence of BAY and DT2, the PDE 3 inhibitor CILO and the PDE 5 inhibitors VAR or 
ZAP, significantly increased  phosphorylation at Ser157 compared to BAY alone (Fig. 3A). 
PKI increased Ser157 phosphorylation induced by BAY (Fig. 3B); however, PDE inhibition  
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Fig. 1. (A) Effect of kinase inhibitors on BAY 41-2272 (BAY)-induced VASPSer157 
phosphorylation. VSMCs were pretreated with PKI, DT2, CALC or vehicle for 30 min prior 
to stimulation with BAY (10uM) for 60 minutes (n=15). (B) Effect of kinase inhibitors on 
BAY-induced VASPSer239 phosphorylation. VSMCs were pretreated with PKI, DT2, CALC 
or vehicle for 30 min prior to stimulation with BAY (10uM) for 60 minutes (n=15). Values are 
the means ± SE. * = different from vehicle (P<0.05). 
 
Fig. 2. (A) Effect of PKI and DT2 on BAY-induced VASPSer157 phosphorylation. VSMCs 
were pretreated with PKI and DT2 or vehicle for 30 min prior to stimulation with BAY 
(10uM) for 60 minutes (n=5). (B) Effect of PKI and CALC on BAY-induced VASPSer239 
phosphorylation. VSMCs were pretreated with PKI or CALC individually, PKI+CALC or 
vehicle for 30 min prior to stimulation with BAY (10uM) for 60 minutes (n=5). Values are the 
means ± SE. * = different from vehicle (P<0.05); † = different from vehicle and BAY (P<0.05).  
had no further effect on Ser157 phosphorylation. BAY-induced Ser239 phosphorylation was 
potentiated only in the presence of PKI and the PDE 5 inhibitor ZAP (Fig 3C). Neither an 
inhibitor of PKA nor PKG and PDEs had any effect on Ser239 in any other instance (data not 
shown).  
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Fig. 3. (A) Effect of DT2 and PDE inhibitors on BAY-induced VASPSer157 phosphorylation. 
VSMCs were pretreated with DT2 alone or CILO, ROL, VAR, or ZAP in the presence of DT2 
or vehicle for 30 min prior to stimulation with BAY (10uM) for 60 minutes (n=13). (B) Effect 
of PKI and PDE inhibitors on BAY-induced VASPSer157 phosphorylation. VSMCs were 
pretreated with PKI alone, CILO, ROL, VAR, or ZAP in the presence of PKI, or vehicle for 30 
min prior to stimulation with BAY (10uM) for 60 minutes (n=8). (C) Effect of PKI and PDE 
inhibitors on BAY 41-2272 (BAY)-induced VASPSer239 phosphorylation. VSMCs were 
pretreated with PKI alone, CILO, ROL, VAR, or ZAP in the presence of PKI, or vehicle for 30 
min prior to stimulation with BAY (10uM) for 60 minutes (n=14). Values are the means ± SE. 
* = different from BAY (P<0.05). 
3.3 Effect of kinase inhibitors on cyclic nucleotide analog-induced VASP 
phosphorylation 
Since BAY increases cAMP and cGMP (Joshi et al., 2011; Mendelev et al., 2009; Stasch et al., 
2001; Stasch et al., 2009) as well as the activity of their respective kinases (Joshi et al., 2011), 
and considering that both kinases can phosphorylate VASP at either kinase-preferred site 
(Butt et al., 1994), cyclic nucleotide analogs were used to determine the kinase(s) specifically 
involved in VASP phosphorylation. VSMCs were incubated with selective kinase inhibitors 
prior to addition of a cAMP or cGMP analog. Results show that 8-Br-cAMP alone failed to 
significantly increase phosphorylation at Ser157 or Ser239, but PKI significantly increased 
phosphorylation at both sites induced by the analogs (Figs. 4A, 4B). Neither DT2 nor CALC 
had an effect on VASP phosphorylation in the presence of 8Br-cAMP. Additionally, when 
using 8Br-cAMP multiple kinase inhibition had no effect greater than that of PKI alone at 
either site (data not shown).  
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Fig. 4. (A) Effect of kinase inhibitors and 8Br-cAMP on VASPSer157 phosphorylation. VSMCs 
were pretreated with PKI, DT2, CALC or vehicle for 30 min prior to stimulation with 8Br-
cAMP (10uM) for 30 minutes (n=10). (B) Effect of kinase inhibitors and 8Br-cAMP on 
VASPSer239 phosphorylation. VSMCs were pretreated with PKI, DT2, CALC or vehicle for 
30 min prior to stimulation with 8Br-cAMP (10uM) for 30 minutes (n=10). Values are the 
means ± SE. * = different from vehicle (P<0.05). 
In comparison, in these cells 8Br-cGMP alone failed to increase Ser157 phosphorylation; 
however, co-treatment with PKI or CALC increased Ser157 phosphorylation (Fig. 5A). On the 
other hand, 8Br-cGMP alone significantly increased phosphorylation at Ser239 and a trend 
for potentiation by PKI was observed (p = 0.059; Fig. 5B).  
Co-treatment with an inhibitor of PKG and PKC blunted the increase induced by 8-Br-cGMP 
at Ser239 (Fig. 6).  
 
Fig. 5. (A) Effect of kinase inhibitors and 8Br-cGMP on VASPSer157 phosphorylation. VSMCs 
were pretreated with PKI, DT2, CALC or vehicle for 30 min prior to stimulation with 8Br-
cGMP (10uM) for 30 minutes (n=10). (B) Effect of kinase inhibitors and 8Br-cGMP on 
VASPSer239 phosphorylation. VSMCs were pretreated with PKI, DT2, CALC or vehicle for 
30 min prior to stimulation with 8Br-cGMP (10uM) for 30 minutes (n=10). Values are the 
means ± SE. * = different from vehicle (P<0.05). 
www.intechopen.com
 
Multiple Kinase Involvement in the Regulation of Vascular Growth 
 
139 
 
Fig. 6. Effect of CALC and DT2 on 8Br-cGMP-induced VASPSer239 phosphorylation. VSMCs 
were pretreated with CALC and DT2 or vehicle for 30 min prior to stimulation with 8Br-
cGMP for 30 minutes (n=8). Values are the means ± SE. * = different from vehicle (P<0.05); † 
= different from 8Br-cGMP (P<0.05).  
3.4 Effect of BAY on Kinase activity 
To determine if BAY increases kinase activity, VSMCs were pretreated with inhibitors of 
kinases prior to stimulation with BAY and selective kinase activity assays were performed. 
BAY increased the activity of PKA ~86% from (0.0278 ± 0.0223 to 0.0519 ± 0.0415). PKI 
decreased the activity back to control levels (0.0214 ± 0.0160). Similarly, BAY increased the 
activity of PKG ~55% from (0.0108 ± 0.0042 to 0.0167 ± 0.007) and DT2 decreased the activity 
back to control levels (0.0116 ± 0.003).  
3.5 Effect of kinase inhibitors and BAY on Proliferation 
Previously we concluded that BAY inhibits proliferation of both rat A7R5 (Mendelev et al., 
2009) and rat primary VSMCs (Joshi et al., 2011). To determine the influence of kinases on 
BAY-induced growth suppression, three complementary assays were performed. In the 
MTT assay, a mitochondria reductase-dependent approach, cells were pretreated with 
kinase inhibitors prior to stimulation with BAY. BAY (non-significantly) decreased 
proliferation (~25%) after 24 hrs, and inhibition of either PKA or PKG significantly 
potentiated this effect (Fig. 7A). Using the BrdU assay, BAY significantly inhibited DNA 
replication after 48 hours, yet inhibition of any individual kinase had no further effect at this 
time point (Fig. 7B). Using hemocytometry, BAY reduced cell numbers after both 48 (Fig. 
7C) and 72 hrs (Fig. 7D). Inhibition of PKA at 48 hrs (Fig. 7C) and either PKA or PKG at 72 
hrs (Fig. 7D) potentiated this effect. On the other hand, a lower concentration of DT2 (1µM) 
had no effect at 72 hrs (Fig. 7E). The Neutral red and MTT assays done at 16 hrs demonstrate 
that BAY and all inhibitor combinations were not cytotoxic (data not shown). 
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Fig. 7. (A) MTT assay to test the effect of PKI, DT2 and BAY on proliferation. VSMCs were 
pretreated with PKI, DT2 or vehicle for 30 min prior to stimulation with BAY (10uM) for 24 
hours (n=9). (B) BrdU assay to test the effect of PKI, DT2, CALC and BAY on proliferation. 
VSMCs were pretreated with PKI, DT2, CALC or vehicle for 30 min prior to stimulation 
with BAY (10uM) for 48 hours (n=10). (C) Hemocytometry assay to test the effect of PKI, 
DT2 and BAY on proliferation.  VSMCs were pretreated with PKI, DT2 or vehicle for 30 min 
prior to stimulation with BAY (10uM) for 48 hours (n=7). (D)  Hemocytometry assay to test 
the effect of PKI, DT2 and BAY on proliferation.  VSMCs were pretreated with PKI, DT2 or 
vehicle for 30 min prior to stimulation with BAY (10uM) after 72 hours (n=16). Values are 
the means ± SE. * = different from vehicle (P<0.05); † = different from vehicle and BAY 
(P<0.01). (E)  Hemocytometry assay to test the effect of PKI, DT2 and BAY on proliferation.  
VSMCs were pretreated with PKI, DT2 or vehicle for 30 min prior to stimulation with BAY 
(10uM) for 72 hours (n=4). Values are the means ± SE. * = different from vehicle (P<0.05); † = 
different from vehicle and BAY (P<0.05). 
3.6 Effect of kinase inhibitors and BAY on Migration 
Previously we observed that BAY inhibits cell migration in rat primary VSMCs (Joshi et al., 
2011). In order to determine the role of kinases on this anti-migratory effect of BAY, VSMCs 
were pretreated with inhibitors of PKG, PKA or PKC prior to stimulation with BAY and 
migration was assessed using the wounding assay. BAY inhibited migration ~40% after 6 
hours and co-incubation of BAY with DT-2 or CALC inhibited migration ~13% or ~17%, 
respectively (data not shown).  
3.7 The effect of kinase inhibitors on BAY-induced VASP phosphorylation in high 
passaged rat primary VSMCs   
In comparison to studies performed at low passage, in higher passage VSMCs (passage > 6) 
either PKI or two chemically dissimilar inhibitors of PKG, DT3 and KT5823, significantly 
increased phosphorylation of VASP at Ser157 but had no effect at Ser239 (Suppl. Figs. 1A and 
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1B, resp.). Notably, in these higher passage cells inhibition of PKC by CALC did not affect 
phosphorylation at either site versus that of BAY alone. In these cells, inhibition of multiple 
kinases had no effect on Ser157 but any combination of kinase inhibitors inhibited VASP 
phosphorylation at Ser239 (data not shown). 
 
Suppl. Fig. 1. (A) Effect of kinase inhibitors on BAY 41-2272 (BAY)-induced VASPSer157 
phosphorylation. Higher passaged (p > 6) VSMCs  were pretreated with PKI, DT2, DT3, KT, 
CALC or vehicle for 30 min prior to stimulation with BAY (10uM) for 60 minutes (n=8). 
Values are the means ± SE. * = different from BAY (P<0.05). (B) Effect of kinase inhibitors on 
BAY-induced VASPSer239 phosphorylation. Higher passaged (p > 6) VSMCs were pretreated 
with PKI, DT2, DT3, KT, CALC or vehicle for 30 min prior to stimulation with BAY (10uM) 
for 60 minutes (n=9). Values are the means ± SE. * = different from vehicle (P<0.05). 
3.8 Effect of kinase inhibitors on cyclic nucleotide analog-induced VASP 
phosphorylation  
In higher passage VSMCs (p > 6), 8-Br-cGMP alone increased phosphorylation at Ser239 only 
(Suppl. Figs. 2A, 2B), and kinase inhibition was without effect at either site.  
 
Suppl. Fig. 2. (A) Effect of kinase inhibitors and 8Br-cGMP on VASPSer157 phosphorylation. 
VSMCs were pretreated with PKI, DT2 or vehicle for 30 min prior to stimulation with 8Br-
cGMP (10uM) for 30 minutes (n=3). (B) Effect of kinase inhibitors and 8Br-cGMP on 
VASPSer239 phosphorylation. VSMCs were pretreated with PKI, DT2, CALC or vehicle for 
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30 min prior to stimulation with 8Br-cGMP (10uM) for 30 minutes (n=21). Values are the 
means ± SE. * = different from vehicle (P<0.05). 
8-Br-cAMP had no effect on site-specific VASP phosphorylation (Suppl. Fig 3A, 3B.). 
However, PKI further increased 8-Br-cAMP-induced phosphorylation at Ser239 (Suppl. Fig. 
3B). In VSMCs p > 6 any combination of kinase inhibitors did not affect cAMP or cGMP-
selective VASP phosphorylation (data not shown).  
 
Suppl. Fig. 3. (A) Effect of 8Br-cAMP on VASPSer157 phosphorylation. VSMCs were 
stimulated with 8Br-cAMP (10uM) for 30 minutes (n=15). (B) Effect of kinase inhibitors and 
8Br-cAMP on VASPSer239 phosphorylation. VSMCs were pretreated with PKI, DT2 or 
vehicle for 30 min prior to stimulation with 8Br-cAMP (10uM) for 30 minutes (n=20). Values 
are the means ± SE. * = different from vehicle (P<0.05). 
3.9 Effect of BAY on Kinase expression  
In untreated VSMCs, Western analysis shows that there is an increase in total PKA in 
passage 6 cells versus passage 2 cells, yet concentration-dependent stimulation with BAY 
did not alter the amount of total PKA in either cohort (Suppl. Fig. 4A). Interestingly, BAY 
(at 10 µM) largely increased the amount of phosphorylated PKA (at Ser338) in p6 VSMCs 
but not in p2 cells (Suppl. Fig. 4A). In comparison, the amount of basal untreated PKG 
decreased with increasing passage, and stimulation with BAY had no additive effect 
(Suppl. Fig. 4B).  
4. Discussion 
The sGC signal transduction system plays an important regulatory role in cardiovascular 
disease due to the production of cyclic nucleotides and their impact on downstream 
effectors. VSMCs primarily regulate vascular tone and contraction and are important in the 
medial layer of arteries. In animal models of vascular injury, intimal and medial thickening 
is attributed to phenotypic switching of resident VSMCs and their proliferation and 
migration from the adventitia and media to the intimal space (Janssens et al., 1998; 
Kawashima et al., 2001; von der Thusen et al., 2004). Therefore, augmentation of neointimal 
formation in iatrogenic response to therapeutic intervention compromises flow and 
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increases the risk of a cardiac event. For that reason understanding the cellular mechanisms 
involved in vascular growth is of critical importance.  
 
Suppl. Fig. 4. (A) Western analysis for Protein Kinase A (PKA) and phosphorylated-
PKASer338. VSMCs cytosolic preparations were incubated with antibodies generated against 
PKA and phospho-PKA. (B) Western analysis for Protein Kinase G (PKG). VSMCs cytosolic 
preparations were incubated with an antibody generated against PKG.  
In this study we provide sound evidence that BAY, a synthetic stimulator of sGC, increases 
the activity of protein kinases and downstream effectors and that this system has the ability 
to control  growth of VSM. Novel results show that activity from PKA, PKG and PKC has 
the capacity to increase phosphorylation of cellular proteins including VASP, a multi-
functional cytoskeletal protein capable of regulating VSM cell proliferation and migration. 
Notably, the implication of multiple kinases in the regulation and activation of VASP 
provides evidence for potential crosstalk among otherwise distinct kinases within the cell. 
Functionally, strong evidence is presented linking cyclic nucleotide-mediated kinase 
activation and VASP phosphorylation with inhibition of VSM growth through modulation 
of proliferation and migration. BAY-induced site-specific VASP phosphorylation is 
regulated by kinases even though cross-talk exists among these (and perhaps other) kinases 
in VSM. These data demonstrate the importance of understanding cyclic nucleotide-directed 
kinases in regulating signaling proteins and their roles for inducing specific cellular 
responses. 
VSMC proliferation, a critical mechanism in vessel remodeling, has been reported to be 
positively controlled by phosphorylation of VASP at Ser157 in VSMCs (Chen et al., 2004). 
VASPSer157 is the site preferentially phosphorylated by PKA, but evidence suggests that both 
PKG and PKC can also phosphorylate Ser157 (Butt et al., 1994; Chitaley et al., 2004). In this 
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study we report that inhibition of PKA alone has no effect on Ser157 phosphorylation of 
VASP induced by BAY (Fig 1A); however, in the presence of a PKG inhibitor 
phosphorylation at this site is increased (Fig 2A). On the other hand, VASPSer239 is the site 
reported to be preferentially phosphorylated by PKG (Butt et al., 1994), but PKA can also 
phosphorylate this site (Butt et al., 1994). In this study, inhibition of PKG alone had no effect 
on VASP phosphorylation at Ser239 induced by BAY (Fig. 1B); however, in the presence of an 
inhibitor of PKC, BAY-induced phosphorylation was increased. These intriguing results 
demonstrate that there is crosstalk among these kinases in response to VASP 
phosphorylation induced by BAY: with respect to Ser157, PKA and PKG are primarily 
involved, whereas at Ser239 the major kinases are PKA and PKC.  
Cyclic nucleotide activity and localization in cells is regulated by PDEs which modulate the 
levels of cyclic nucleotide levels and maintains them at a steady state. Moreover, kinases 
have been shown to regulate PDE activity (Bender et al., 2006). It has been reported that PKA 
phosphorylates and increases the activities of PDE3 and 4 (Bender et al., 2006; Degerman et 
al., 1997; Houslay et al., 2007), while an increase in cGMP binding and phosphorylation by 
PKG increases the activity of PDE5 (Bender et al., 2006; Rybalkin et al., 2002). BAY has been 
shown to increase cyclic nucleotide content in VSMCs (Joshi et al., 2011; Mendelev et al., 
2009); therefore, it is logical that PDE and kinase activity could potentially be modulated by 
BAY treatment. Preliminary data suggest that with respect to Ser157, inhibition of PDE5 
increased its phosphorylation while inhibition of PDE3 and PDE4 decreased its 
phosphorylation in response to BAY. Here we demonstrate that inhibition of PDE3 or PDE5 
in the presence of an inhibitor of PKG increases the phosphorylation at this site while 
inhibition of PDE4 had no effect (Fig 3A). In the presence of PKA inhibition, Ser157 
phosphorylation was increased and PDE inhibition had no additional effect (Fig 3B). 
Considering that PDE3 is a cGMP-inhibited PDE, following concomitant inhibition of both 
PDE5 and PKG, the resulting increase in cAMP and PKA is expected as an enhancement of 
BAY-induced signaling. The same observation is seen following simultaneous inhibition of 
PKG and PDE5, as there is an increase in cGMP which could then inhibit PDE3 and increase 
cAMP leading to additive phosphorylation at Ser157. On the other hand, in the presence of an 
inhibitor of PKA and individual PDE inhibitors, no further phosphorylation is shown at 
Ser157 suggesting that this previously observed inhibitory effect is rescued.  
At VASPSer239, preliminary data suggest that inhibition of PDE activity decreased 
phosphorylation at this site in response to BAY. Here we demonstrate that in the presence of 
an inhibitor of PKA or PKG, inhibition of PDEs no longer decreases Ser239 phosphorylation 
and in fact, inhibition of PDE5 with ZAP in the presence of PKI increased Ser239 
phosphorylation (Fig 3C). These results support involvement of kinases in the regulation of 
PDEs. In this study we are inhibiting activation of PDEs via kinases as well as inhibiting the 
actual PDE, thereby increasing the cyclic nucleotide content of the cell and as a result 
increasing phosphorylation of VASP. This supports the argument that an increase in both 
cyclic nucleotides in a cell at the same time is inhibitory because two kinases are active 
simultaneously thereby activating opposing pathways. In addition, these findings confirm 
the theory of intracellular compartmentalization of second messengers and their effectors as 
described elsewhere (Di Benedetto et al., 2008; Houslay et al., 2007; Zaccolo et al., 2002).  
Activation of kinases in other pathways may negatively regulate phosphorylation of VASP. 
It is reported that PKG is the primary kinase responsible for phosphorylation of Ser239 (Butt 
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et al., 1994); in turn, PKG inhibition would hinder Ser239 phosphorylation and PKA would 
then become the primary kinase responsible for phosphorylation at this site. To further add 
to the complexity of these findings and to demonstrate the importance of kinase regulation 
and localization of proteins we demonstrate that inhibition of PDE5 in the presence of an 
inhibitor of PKA potentates the phosphorylation at Ser239. This demonstrates that cGMP 
does indeed directly phosphorylate VASP at this site independent of cAMP/PKA signals 
(Fig. 3C).    
BAY has been shown to increase the content of both cAMP and cGMP in VSMCs (Joshi et al., 
2011; Mendelev et al., 2009); therefore, to directly assess its mechanisms of action and what 
kinases may be involved in site specific phosphorylation of VASP, cyclic nucleotide analogs 
which directly activate PKA and PKG were used. 8Br-cAMP is a direct activator of PKA, the 
kinase which directly phosphorylates Ser157 (Butt et al., 1994). As one would expect addition 
of this analog should increase Ser157 phosphorylation of VASP due to the increase in PKA 
activity. We did not observe an increase with the analog alone (Fig. 4A); however, inhibition 
of PKA in the presence of the analog significantly increased VASP phosphorylation at this 
site (Fig. 4A). Interestingly, inhibition of PKG or PKC in the presence of 8Br-cAMP had no 
effect at Ser157. Although PKG is reported to be the primary kinase responsible for 
phosphorylation of Ser239 there could potentially be crosstalk involving other kinases at this 
site. This observation was evidenced with Ser239 phosphorylation whereby inhibition of PKA 
increased phosphorylation in the presence of the cyclic nucleotide analog (Fig. 4B). These 
data could provide an argument against the selectivity of the analogs in activating kinases 
because 8Br-cAMP may be activating PKG or some other protein that in reality is 
phosphorylating VASP. 8Br-cGMP is a direct activator of PKG and alone has no effect on 
Ser157 but markedly increases Ser239 as expected (Fig 5A, 5B). However, inhibition of PKA 
and PKC increased phosphorylation at Ser157 in the presence of 8Br-cGMP (Fig 5A). 
Inhibition of PKA slightly increased Ser239 phosphorylation above that of 8Br-cGMP alone 
(Fig 5B), while inhibition of either PKG or PKC slightly but not significantly increases 
phosphorylation. We could infer here that PKA and PKG are competing for the same site; 
therefore inhibition of PKA increases the phosphorylation at any particular site. 
Alternatively, we could conclude that PKA negatively regulates phosphorylation of VASP 
because inhibition of PKA increases phosphorylation of both sites. In any event, these 
results demonstrate that cyclic nucleotide analogs and BAY use different mechanisms to 
phosphorylate VASP. This is demonstrated in the results shown here whereby inhibition of 
both PKG and PKC (Fig. 6) inhibit phosphorylation at Ser239. We can conclude that both 
PKG and PKC are actively involved in phosphorylation of Ser239 in response to 8Br-cGMP. 
In comparison, multiple kinase inhibition had no effect on 8Br-cAMP in its phosphorylation 
of VASP. These data clearly demonstrate that phosphorylation and thus regulation of VASP 
at these sites is complex in that all three major protein kinases (PKA/G/C) are involved. 
Furthermore, BAY, originally characterized as a direct activator of sGC, equally increases 
both PKA and PKG activity in these cells (Fig. 7). Thus, it appears that PKA may be the 
more active kinase involved in the phosphorylative control of VASP in VSM.  
Direct involvement of PKA in BAY-mediated reduction in proliferation is seen in both the 
MTT and hemocytometry results in this study, which suggest that PKA activity is necessary 
for proliferation of VSMCs (Fig 8). The involvement of PKA in proliferation was previously 
suggested by Chen and colleagues (Chen et al., 2004) where they found that phosphorylation 
of VASP by PKA stimulates proliferation. The difference between our study and that of 
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Chen and associates is that our study uses rat primary VSMCs and phosphorylation of 
VASP was in response to a pharmacologic stimulus, whereas theirs was done in VASP 
knockout (KO) mice where wild type or mutant VASP was transduced and phosphorylation 
induced by NO. These results suggest that the cellular mechanism of inhibition of cell 
growth induced by BAY is precise and unique to the drug. Interestingly, in our study the 
effects of PKG on the ability of BAY to inhibit proliferation in the MTT and BrdU assays 
(Figs. 8A, 8B) is similar to that of PKA; however, according to hemocytometric analysis these 
effects are not apparent until a later timepoint of 72 hrs (Fig 8C).  
In the study by Chen and others (Chen et al., 2004), the investigators show that genetic KO 
of VASPSer239 promotes migration. In our previous study (Joshi et al., 2011), we showed that 
BAY phosphorylates Ser239 and in turn inhibits migration, which appears specific as a 
mechanism of action since inhibition of PKG fully reversed this effect. In the current study, 
data support these previous findings. Interestingly, the effect that PKG has on migration is 
similar to what is seen with PKC. Considering the influence of 8Br-cGMP on VASPSer239 (Fig. 
6), these data support the involvement of PKG and PKC with VASP phosphorylation at 
Ser239 and their regulatory role in migration of VSMCs.  
To summarize these functional data, with respect to proliferation VASPSer157 and PKA 
appear to be more involved and for migration VASPSer239 and PKG may be more involved 
in VSMCs. In an instance where one kinase is reduced or rendered dysfunctional, other 
kinases may compensate providing multiple kinase regulation of any particular functional 
event. Additionally, these data demonstrate that PDEs help to maintain tight regulation of 
cyclic nucleotides in these cells. Inhibition of PDEs increases the activity of proteins 
involved in phosphorylation of VASP, and inhibition or feedback regulation occurs because 
both cyclic nucleotides are high at the same time demonstrating the importance of 
compartmentalization of proteins. It is also possible that BAY increases the activity of some 
alternate pathways that may be involved with VASP phosphorylation in these cells.  
In separate experiments, higher passaged cells were used to evaluate the influence of 
phenotypic switching in the response to cyclic nucleotide and kinase signaling. In these cells 
(p>6) treated with BAY, inhibition of PKA increased phosphorylation of VASP at Ser157 but 
had no effect on Ser239, while inhibition of PKG increased phosphorylation of Ser157 but had 
no effect on Ser239 (Suppl. Fig. 1). On the other hand, inhibition of any kinase in the presence 
of a cyclic nucleotide analog had no effect (Suppl. Figs 2-3), except in the presence of 8Br-
cAMP at Ser239 (suppl. Fig. 3B). We also show that the amounts of total PKA and 
phosphorylated PKA increase and that the amount of PKG protein decreases with passage 
(suppl. Figs. 5A, 5B). Thus, these signaling events and in particular kinase expression must 
be considered with elevated passage as a model of phenotypic changes associated with 
injury or disease. 
5. Conclusion 
In conclusion, in this study we demonstrate that: 1) BAY increases phosophorylation of VASP 
at both Ser157 and Ser239; 2) BAY increases both PKA and PKG activity; 3) BAY reduces 
proliferation and migration in VSMCs; 4) inhibition of PKA in response to BAY augments 
inhibition of proliferation of VSMCs yet has no effect on migration; 5) multiple kinases appear 
to be involved in regulation of VASP phosphorylation; 6) PKA appears to be the kinase that is 
most active in these cells in response to BAY, and 7) kinases are involved in regulation of PDEs 
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that regulate VASP phosphorylation in VSMCs. These findings provide valuable details about 
the biochemical cell signaling associated with cyclic nucleotide second messengers in VSM and 
highlight BAY as a potential anti-growth modulator in VSM.  
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